Black Health Matters (BHM), the nation's leading health equity platform dedicated to improving the health outcomes of Black ...

In the Phase 2 ALPACA study, lepodisiran significantly reduced Lp(a) levels by an average of 93.9% over the 60 to 180-day period after treatment with the highest tested dose (400 mg), meeting the ...

Lepodisiran 400 mg reduced Lp(a) levels by 93.9% over 60-180 days, with sustained reductions of 74.2% at 1.5 years. No serious adverse events were linked to lepodisiran, and the Phase 3 ACCLAIM-Lp ...

The namesake WtP is maintained for consistency. Our new followup SaT provides robust, efficient and adaptable sentence segmentation across 85 languages at higher performance and less compute cost.